CN1917868A - Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis - Google Patents
Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis Download PDFInfo
- Publication number
- CN1917868A CN1917868A CNA2005800041621A CN200580004162A CN1917868A CN 1917868 A CN1917868 A CN 1917868A CN A2005800041621 A CNA2005800041621 A CN A2005800041621A CN 200580004162 A CN200580004162 A CN 200580004162A CN 1917868 A CN1917868 A CN 1917868A
- Authority
- CN
- China
- Prior art keywords
- salt
- pharmaceutical composition
- isoleucine
- serine
- folic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 title claims abstract description 35
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 30
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 title claims abstract description 29
- 239000011573 trace mineral Substances 0.000 title claims abstract description 21
- 235000013619 trace mineral Nutrition 0.000 title claims abstract description 21
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 229960000304 folic acid Drugs 0.000 title claims abstract description 15
- 239000011724 folic acid Substances 0.000 title claims abstract description 15
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 15
- 201000004681 Psoriasis Diseases 0.000 title abstract description 7
- 239000011651 chromium Substances 0.000 claims abstract description 20
- 239000011669 selenium Substances 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229960000310 isoleucine Drugs 0.000 claims abstract description 16
- 229960001153 serine Drugs 0.000 claims abstract description 16
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 10
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 9
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 9
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims abstract description 9
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930182844 L-isoleucine Natural products 0.000 claims abstract description 6
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims description 19
- 230000001185 psoriatic effect Effects 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 10
- 230000001537 neural effect Effects 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 8
- 230000037213 diet Effects 0.000 claims description 8
- 229910052721 tungsten Inorganic materials 0.000 claims description 8
- 239000010937 tungsten Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 150000008575 L-amino acids Chemical class 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- DIMMBYOINZRKMD-UHFFFAOYSA-N vanadium(5+) Chemical class [V+5] DIMMBYOINZRKMD-UHFFFAOYSA-N 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 abstract description 12
- 150000001413 amino acids Chemical class 0.000 abstract description 11
- 229910052718 tin Inorganic materials 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010048768 Dermatosis Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 235000021152 breakfast Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Biological medical means for treating psoriasis are disclosed. The invention relates to the use of L-serine (Ser) and L-isoleucine (Ile) for the manufacture of a pharmaceutical composition for treating or preventing psoriasis. The invention further relates to a pharmaceutical composition comprising said amino acids as active ingredients. Preferably the composition further comprises at least one essential trace element selected from the group consisting of chromium (Cr), tin (Sn), selenium (Se), vanadium (V), wolfram (W) and zinc (Zn), and folic acid.
Description
Invention field
The present invention relates to the natural biological composition is used for the treatment of or prevents purposes in the psoriatic pharmaceutical composition in preparation.The invention still further relates to and contain the pharmaceutical composition of natural biological composition as independent active constituents of medicine.Said composition has curative effect to dermatosis.
Background of invention
Psoriasis is a kind of dermatosis with variform, it is characterized in that extensor (extensor) surface at health forms the erythema of covering squama.As if psoriasis is generally chronic disease, and it is relevant with certain genetic predisposition.These patients' treatment complexity and expense costliness, but the result who cures is uncommon.When disease progression, also may involve the joint, and cause serious pain, limited patient's activity.The Therapeutic Method of standard is recently without any the change of fourth point, and common therapy remains light treatment, some ointment and cortisone.Do not design effective natural therapy as yet.Therefore, for the psoriatic method of improved treatment very big demand is arranged, this method should be effectively, and is simple, cheap and with no harmful side-effects.
In the world today, cancer is to cause one of main causes of death, has spent ample resources in searching aspect this class treatment of diseases method.Cancer is routinely by performing the operation, radiate or treating with cytostatic agent.Alternative treatment method comprises the biology that for example is referred to as the biological immune therapy and associating (Tallberg, the Thomas.Development of aCombined Biological and Immunological Cancer Therapy Modality.Areview of Bio-immunotherapy.J.Austr.Coll.Nutr.﹠amp of immunization therapy form; Env.Med.2003:22 3-21 page or leaf).In the biological immune therapy, give the natural biological composition to the cancer patient, this natural biological composition is made up of the mixture of aminoacid and trace element, randomly with neural lipid material (neurogenic lipids) and/or combination of vitamins.Tested the different mixtures of these compositions already at multi-form cancer.These mixture preferably give as the food enlargement.
The present invention is based on following surprising discovery, promptly during by biological immune therapy for treatment of cancer patient, some dermatosiss of unexpectedly also suffering from psoriatic cancer patient obviously disappear, perhaps the symptom of dermatosis obviously alleviates, although the treatment of cancer that they accepted not is to be dermopathic at them.This as if irrelevant with malignant disease to psoriatic good effect, and any type of cancer of being suffered from the patient is also uncorrelated.
The present invention provides the natural biological composition to be used for the treatment of or to prevent purposes in the psoriatic pharmaceutical composition in preparation now.
The present invention also provides a kind of cheap and safe pharmaceutical composition that contains the natural biological composition to be used for the treatment of or has prevented psoriasis.
By the individual administration natural biological composition to needs, the present invention also provides a kind of selectable treatment or has prevented psoriatic method.
The invention summary
The present invention relates to L-amino acid serine (Ser) and isoleucine (Ile) is used for the treatment of or prevents purposes in the psoriatic pharmaceutical composition in preparation.Described aminoacid exists with non-binding form (before being known as single amino acid), this means that this aminoacid is not contained in peptide or protein or any other macromole or the conjugate, but it can exist with the trace element ion of compositions form with complex.
The invention still further relates to pharmaceutical composition, it contains L-amino acid serine (Ser) and isoleucine (Ile), randomly with at least a trace element associating that is selected from chromium (Cr), stannum (Sn), selenium (Se), vanadium (V) and tungsten (W), and/or together with folic acid as independent active constituents of medicine.
The invention also discloses treatment or prevent psoriatic method, this is to give the L-amino acid serine (Ser) of pharmaceutically active amount and isoleucine (Ile) realization by the individuality to needs.
Some embodiment preferred of the present invention are set forth among the dependent claims.
Detailed Description Of The Invention
According to suffering from the analysis of the natural biological composition that psoriatic cancer patient absorbs, clearly illustrate that, accept in the biological immune therapy employed some aminoacid with specific basic trace element metal ion at them, their dermatosis has been produced positive clinical effectiveness.In these cancer patients' intimate kinsfolk, those are in others health, but the people who also experiences the psoriasis outbreak also can produce favourable clinical effectiveness behind the same natural diet composition of picked-up.
Therefore, those not cancered psoriatics have been studied.In a large amount of cases of test, describe these active diet compositions in detail.Augment the preparation that oral prescription that form opens for those patients is based on the combination that contains aminoacid isoleucine (Ile) and serine (Ser) with food.Described two seed amino acids give with the amino acid whose form of L-.
Except Ile and Ser, compositions preferably also contains at least a basic trace element that is selected from chromium (Cr), stannum (Sn), selenium (Se), vanadium (V), tungsten (W) and zinc (Zn).Randomly, trace element also comprises, for instance, and manganese (Mn).Be biologically active, trace element should be ionic species, and for this reason, they give as the form of salt in the practice.The salt that preferably has neutral taste should avoid having the salt of strong or taste inferior.
Preferably, treat or prevent psoriatic preparation also to contain the folic acid of physiological amount.
The treatment that success is used according to the present invention is based on oral administration L-serine and L-isoleucine, randomly and basic trace element and folic acid together as active component.According to one embodiment of the invention, compositions is made up of described three constituents basically, i.e. aminoacid, trace element and vitamin.All these compositions all are natural existence and biologically active, this means that they participate in such as such incident biology of metabolic process.Use contains L-serine, L-isoleucine, Cr salt, Sn salt, Se salt, V salt and W salt, and folic acid has been obtained extraordinary effect as the compositions of independent active constituents of medicine.
Compositions for use contains the composition of biological and pharmaceutically active amount, just is enough to reach the composition of amount of the health promotion effect of expectation.As the doctor be readily appreciated that, described amount will be according to individuality and health status thereof, and other factors, for example, body weight, age, nutrition, pressure and environmental factors etc., and different.The example of suitable amount includes but not limited to: L-serine and L-isoleucine respectively are about 2-10g/ days, 2-5g/ days usually.The trace element ion that the use amount of common trace element is generally Cr, Sn, Se, V and W respectively is 0.5-9mg/ days, preferred 1-3mg/ days.Zn can be with about 15mg/ days, and Mn can give with about 50mg/ days dosage.Folic acid used with a small amount of physiological amount of fully establishing, as 1-2mg/ days.
For promoting patient's lymphopoiesis and immune defence, also the neural lipid material of prion-free can be used the patient of above-mentioned combination treatment.For example, neural lipid material can obtain in the brain of healthy piglets.With cerebral tissue boil, freezing and lyophilizing, thereby as previously described, extract the lipid fraction that lipid material obtains prion-free people CancerImmunity.The Effect in Cancer-Immunotherapy of PolymerisedAutologous Tumour Tissue and Supportive Measures.Scand.J.Lab.Invets.1979:39 3-33 pages or leaves such as () Tallberg T. with ether-ethyl alcohol then.Buy neural lipid material and tinning by Finland's Neurofood Ltd. company limited.The recommendation daily intaking amount of neural lipid material is equivalent to about 50-100g brain.
The composition that comprises the compositions of aminoacid, trace element and vitamin can similarly give respectively or with different combinations.For example, can buy their powder respectively, or buy the ready-made powder that comprises all the components.This powder mixture can be by prepackage and is used like this, or as the enlargement of conventional food product, for example, is used in the Yoghurt of patient's breakfast.For consumers, be easy to it together with breakfast absorption or as the snack between the dinner.Because it includes only natural component, forms active food additive, therefore this compensatory Diet Therapy is relatively cheap.Certainly also pharmaceutical composition can be processed into granule, capsule or tablet, it can comprise pharmaceutically acceptable carrier or excipient.Neural lipid product can give with other composition or give respectively at different time simultaneously.Preferred mode is to sneak into neural lipid product in the fruit of dispensing and cold preservation is taken in.
The present invention elaborates by the following examples, and these embodiment should not be interpreted as limiting by any way its scope.Those skilled in the art can make change and the modification that has with the identical beneficial effect described in the literary composition.
Embodiment
With the form of food enlargement some biological activity trace element salt to not cancered psoriatic's orally give isoleucine and serine and milligram quantities, wherein metal ion exists with the biologic activity form.Also comprised a little milligram folic acid in the compositions.Give this natural food enlargement to these patients every day.The biological adjusting of the diet timetable that is used for the treatment of the psoriatic is as follows:
The supportive diet measure of associating:
1. the corresponding L-aminoacid of oral administration: serine (Ser) and isoleucine (Ile) (each 2-5g/ days), together with meals.
2. as the oral basic trace element salt of biologic activity ion, it is a little milligram a dosage level (1-3mg/ days): chromium (CrCl
36H
2O) 6mg (=1.17mg Cr), stannum (SnCl
4SH
2O) 4mg (=1.35mg Sn), selenium Na
2SeO
410H
2O, 6mg (=1.28mg Se), vanadium (Na
2VO
44H
2O), 6mg (=2.5mg V), tungsten (Na
2WO
42H
2O), 4mg (=2.3mg W).Some patient also accepts the zinc gluconate that daily dose is equivalent to the 15mg zinc ion, and some patient's acceptable dose is the manganese sulfate of 140mg/ days (=2.5mg Mn).
3. the folic acid (1-2mg/ days) of physiological amount in a small amount.
4. the extra acceptance of some patient is equivalent to the diet (by Finland Neurofood Ltd. company limited purchase and canned) of the neural lipid material that contains prion-free of about 50g brain.
5. the patient accepts the good mixture powder that contains composition 1-3 of prepackage, thereby and suggestion powder be blended in their breakfast Yoghurt obtain a day ration.
6. the clinical response that arrives is according to the observation adjusted dosage level, and carries out related with weight in patients.
In the time of some months, in more than ten patient of test, observed the positive therapeutic effect.The local skin speckle becomes to stimulate and alleviates, and some complete obiteration.Arthralgia goes down.Under the situation of compositions continuous use, the effect of some case lasts up to 20 years.Positive clinical effectiveness demonstrates slight individual variation, belongs to the amount of these biotic components and the difference of relative amount and weight in patients.In some case, the associating of independent Ile and trace element salt can produce certain good effect, but in other patient the seemingly essential cofactor of Ser.This variation may be relevant with some inherited character of psoriatic.Be intended to remedy this Diet Therapy of the metabolic deficiency due to this disease, irrelevant with any side reaction that arbitrary volunteer experienced of test.This food additive can be brought into play the lasting effect that alleviates to the psoriatic.
Claims (10)
1. following material is used for the treatment of or prevents purposes in the psoriatic pharmaceutical composition in preparation:
A) L-amino acid serine (Ser) and isoleucine (Ile),
B) trace element chromium (Cr), stannum (Sn), selenium (Se), vanadium (V) and tungsten (W) and
C) folic acid.
2. purposes according to claim 1, the pharmaceutical composition that is used to prepare also contain zinc (Zn).
3. purposes according to claim 1 and 2, the pharmaceutical composition that is used to prepare also contain manganese (Mn).
4. purposes according to claim 1, the pharmaceutical composition that is used to prepare contains:
A) L-serine and each 2-5g of L-isoleucine,
B) chromium (Cr) salt, stannum (Sn) salt, selenium (Se) salt, vanadium (V) salt and tungsten (W) each 0.5-6mg of salt and
C) folic acid 1-2mg.
5. according to the described purposes of aforementioned arbitrary claim, the pharmaceutical composition that is used to prepare also contains neural lipid material.
6. according to the arbitrary described purposes of claim 1-4, be used to prepare the pharmaceutical composition of powder form.
7. according to claim 5 or 6 described purposes, be used to prepare diet and augment compositions.
8. pharmaceutical composition, it contains following material as independent active constituents of medicine:
A) L-amino acid serine (Ser) and isoleucine (Ile),
B) trace element chromium (Cr), stannum (Sn), selenium (Se), vanadium (V) and tungsten (W) and optional zinc (Zn) and
C) folic acid.
9. pharmaceutical composition according to claim 8, contain following material as independent active constituents of medicine:
A) serine (Ser) and isoleucine (Ile),
B) chromium (Cr) salt, stannum (Sn) salt, selenium (Se) salt, vanadium (V) salt, tungsten (W) salt and zinc (Zn) salt and
C) folic acid.
The treatment or prevent psoriatic method, wherein give the following material of pharmaceutically active amount to the individuality of needs:
A) L-amino acid serine (Ser) and isoleucine (Ile),
B) trace element chromium (Cr), stannum (Sn), selenium (Se), vanadium (V), tungsten (W) and optional zinc (Zn) and
C) folic acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20040180 | 2004-02-06 | ||
| FI20040180A FI121915B (en) | 2004-02-06 | 2004-02-06 | Composition for the treatment of psoriasis |
| PCT/FI2005/000075 WO2005074910A1 (en) | 2004-02-06 | 2005-02-04 | Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1917868A true CN1917868A (en) | 2007-02-21 |
| CN1917868B CN1917868B (en) | 2010-09-01 |
Family
ID=31725662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800041621A Expired - Fee Related CN1917868B (en) | 2004-02-06 | 2005-02-04 | Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20070258892A1 (en) |
| EP (1) | EP1718290B1 (en) |
| JP (1) | JP4919812B2 (en) |
| CN (1) | CN1917868B (en) |
| AT (1) | ATE466576T1 (en) |
| AU (1) | AU2005210181B2 (en) |
| BR (1) | BRPI0507732A (en) |
| CA (1) | CA2555328C (en) |
| DE (1) | DE602005021062D1 (en) |
| DK (1) | DK1718290T3 (en) |
| ES (1) | ES2344510T3 (en) |
| FI (1) | FI121915B (en) |
| HK (1) | HK1097455A1 (en) |
| NO (1) | NO20063937L (en) |
| PL (1) | PL1718290T3 (en) |
| PT (1) | PT1718290E (en) |
| RU (1) | RU2372899C2 (en) |
| WO (1) | WO2005074910A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470119A (en) * | 2009-07-01 | 2012-05-23 | 皮埃尔·法布尔皮肤化妆品公司 | L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI122450B (en) * | 2007-12-28 | 2012-01-31 | Neurofood Ab Oy | A composition for the treatment of sterile inflammation |
| CN101953846B (en) * | 2010-06-24 | 2011-12-28 | 攀枝花兴辰钒钛有限公司 | Application of medicinal composition to preparing medicament for treating diabetes |
| CA2855854C (en) | 2011-11-21 | 2020-03-31 | The Institute For Ethnomedicine | L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders |
| EP3586849A1 (en) * | 2018-06-29 | 2020-01-01 | Aprofol AG | Folate preparations |
| EP4017278A4 (en) | 2019-08-21 | 2023-09-13 | Brain Chemistry Labs | Compositions comprising a metal and l-serine, and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83775A (en) * | 1987-09-04 | 1991-12-15 | Dexter Chemical Corp | Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis |
| DE3712986A1 (en) * | 1987-04-16 | 1988-10-27 | Marbert Gmbh | MEDICAL PREPARATIONS BASED ON TREASURE EXTRACT, METHOD FOR THE PRODUCTION THEREOF AND USE OF TREATMENT EXTRACT FOR THE PRODUCTION OF COSMETIC PREPARATIONS AND A SPECIAL TREATMENT EXTRACT |
| US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
| CN1080131A (en) * | 1993-04-28 | 1994-01-05 | 王韵三 | A kind of beauty and health care nutraceutical and preparation method |
| US5563132A (en) * | 1994-06-21 | 1996-10-08 | Bodaness; Richard S. | Two-step cancer treatment method |
| US6083293A (en) * | 1997-02-24 | 2000-07-04 | Bath; Virginia L. | Method for enhanced plant protein production and composition for use in the same |
| EP1071414A1 (en) * | 1998-04-24 | 2001-01-31 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
| GB0019327D0 (en) * | 2000-08-08 | 2000-09-27 | Buchanan Baillie Hamilton Paul | Slimming system |
| US20040086583A1 (en) * | 2002-11-01 | 2004-05-06 | Jensen Claude Jarakae | Anti-angiogenesis effects of morinda citrifolia |
-
2004
- 2004-02-06 FI FI20040180A patent/FI121915B/en not_active IP Right Cessation
-
2005
- 2005-02-04 ES ES05708155T patent/ES2344510T3/en active Active
- 2005-02-04 CN CN2005800041621A patent/CN1917868B/en not_active Expired - Fee Related
- 2005-02-04 PT PT05708155T patent/PT1718290E/en unknown
- 2005-02-04 AU AU2005210181A patent/AU2005210181B2/en not_active Ceased
- 2005-02-04 JP JP2006551868A patent/JP4919812B2/en not_active Expired - Fee Related
- 2005-02-04 WO PCT/FI2005/000075 patent/WO2005074910A1/en active Application Filing
- 2005-02-04 CA CA2555328A patent/CA2555328C/en not_active Expired - Fee Related
- 2005-02-04 AT AT05708155T patent/ATE466576T1/en active
- 2005-02-04 US US10/588,051 patent/US20070258892A1/en not_active Abandoned
- 2005-02-04 DE DE602005021062T patent/DE602005021062D1/en active Active
- 2005-02-04 DK DK05708155.6T patent/DK1718290T3/en active
- 2005-02-04 EP EP05708155A patent/EP1718290B1/en active Active
- 2005-02-04 PL PL05708155T patent/PL1718290T3/en unknown
- 2005-02-04 RU RU2006128209/15A patent/RU2372899C2/en not_active IP Right Cessation
- 2005-02-04 BR BRPI0507732-0A patent/BRPI0507732A/en not_active IP Right Cessation
-
2006
- 2006-09-04 NO NO20063937A patent/NO20063937L/en not_active Application Discontinuation
-
2007
- 2007-03-29 HK HK07103397.6A patent/HK1097455A1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470119A (en) * | 2009-07-01 | 2012-05-23 | 皮埃尔·法布尔皮肤化妆品公司 | L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2372899C2 (en) | 2009-11-20 |
| BRPI0507732A (en) | 2007-07-10 |
| WO2005074910A1 (en) | 2005-08-18 |
| ES2344510T3 (en) | 2010-08-30 |
| RU2006128209A (en) | 2008-03-20 |
| PL1718290T3 (en) | 2010-10-29 |
| CN1917868B (en) | 2010-09-01 |
| DE602005021062D1 (en) | 2010-06-17 |
| CA2555328A1 (en) | 2005-08-18 |
| JP2007520532A (en) | 2007-07-26 |
| FI20040180A (en) | 2005-08-07 |
| HK1097455A1 (en) | 2007-06-29 |
| EP1718290A1 (en) | 2006-11-08 |
| NO20063937L (en) | 2006-09-04 |
| ATE466576T1 (en) | 2010-05-15 |
| CA2555328C (en) | 2013-03-26 |
| EP1718290B1 (en) | 2010-05-05 |
| US20070258892A1 (en) | 2007-11-08 |
| JP4919812B2 (en) | 2012-04-18 |
| AU2005210181A1 (en) | 2005-08-18 |
| FI20040180A0 (en) | 2004-02-06 |
| PT1718290E (en) | 2010-07-01 |
| DK1718290T3 (en) | 2010-08-02 |
| AU2005210181B2 (en) | 2010-05-20 |
| FI121915B (en) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| EP2288364B1 (en) | Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances | |
| US20060269617A1 (en) | Supplement compositions and method of use for enhancement of insulin sensitivity | |
| WO1998042211A2 (en) | Nutritional supplements for improving glucose metabolism | |
| CN113244209A (en) | Application of ferric citrate in treating chronic kidney disease patient | |
| CN1917868B (en) | Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis | |
| DE60214849T2 (en) | CHROMIUM / BIOTIN TREATMENT OF DYSLIPIDEMIA | |
| DE3348163C2 (en) | ||
| WO2020221184A1 (en) | Pharmaceutical composition with effect of reducing uric acid | |
| JPH04506597A (en) | Decreased postprandial plasma concentrations of large neutral amino acids | |
| RU2741577C2 (en) | Sublingual or buccal introduction of dim for treating skin diseases | |
| RU2462244C2 (en) | Composition for noninfectious inflammation | |
| CZ297743B6 (en) | Use of acetyl L-carnitine in connection with biotin for treating patients suffering from type 2 diabetes mellitus resistant to insulin | |
| RU2201179C2 (en) | Method for treating diabetic retinopathies | |
| US20130059813A1 (en) | Treatment of dermatological conditions | |
| US20210346334A1 (en) | Nutritional chromium compositions and methods of use | |
| WO2010124322A1 (en) | Bicarbonate solution for bioavailable magnesium and uses thereof | |
| DE60318610T2 (en) | PHARMACEUTICAL ANTIDIABETES COMPOSITION | |
| AT17839U1 (en) | Composition against iron deficiency | |
| DE10238677A1 (en) | Mixture for oral ingestion, useful as a medicament, dietetic product or dietary supplement, comprises defined amounts of vitamins, selenium and zinc | |
| US20190083479A1 (en) | Combination medication | |
| WO2003030890A1 (en) | Immune system activators | |
| MATSUO et al. | Pathophysiological Significance of an Oral Zinc Tolerance Test in Patients with Chronic Hepatic Diseases | |
| DE20212933U1 (en) | Vitamin and trace element mixture for kidney patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NERVE FOOD CO., LTD. Free format text: FORMER OWNER: BIOLOGY IMMUNOTHERAPY CO.,INC, HELSINKI SOCIETY Effective date: 20100326 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: HELSINKI, FINLAND TO: ESPOO, FINLAND |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20100326 Address after: Espoo, Finland Applicant after: Oy Neurofood AB Address before: Helsinki Applicant before: Helsingfors Institution Foer B. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100901 Termination date: 20150204 |
|
| EXPY | Termination of patent right or utility model |